Abstract
There is now overwhelming evidence for the involvement of forebrain cholinergic systems in Alzheimer’s disease and the cognitive processes that subserve learning and memory (Perry et al., 1978; Bigl et al., 1987; Koshimura et al., 1987; Doucette et al., 1986; Ichimiya et al., 1986; Saper et al., 1985;Whitehouse, 1986; McGeer et al., 1984; Mann et al., 1986; Giacobini, 1990; Wenk et al., 1987). Support for the role of forebrain cholinergic systems in learning and memory can be gleaned from innumerable studies in which perturbation of forebrain cholinergic systems, whether through pharmacological means or lesion of the nucleus basalis of Meynert (nbM), has been demonstrated to profoundly impair learning and memory. This literature has been amply reviewed in recent articles and numerous chapters in this book (Wenk and Olton, 1987; Gold and Zornetzer, 1983; Dekker et al., 1991) and will not be reiterated here. In general, however, lesions of the nbM have been shown to impair performance on a very large variety of tasks and in a large and varied number of mammalian species. A smaller, but nevertheless voluminous, literature also attests to the ability of cholinomimetic agents such as physostigmine, oxotremorine, pilocarpine, etc. to at least partially reverse the learning and memory deficits induced by nbM lesions (Haroutunian et al., 1990c; Mandel et al., 1989; Fine et al., 1985; Bhat et al., 1990; Haroutunian et al., 1989b, 1990; Murray and Fibiger, 1985).
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Adell A, Sarna GS, Hutson PH, Cruzon G (1989): An in vivo dialysis and behavioural study of the release of 5-HT by p-chloroamphetamine in resperine-treated rats. Br J Pharmacol 91:206–212
Adolfsson R, Gottfries CG, Roos BE, Winblad B (1979): Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiat 135:216–223
Aghajanian GK, Sprouse JS, Rasmussen K (1987): Physiology of the midbrain serotonin system: In: Psychopharmacology: The Third Generation of Progress, Meltzer HY, ed. New York: Raven Press, pp 141–149
Altman HJ, Normile H (1988): What is the nature of the role of the serotonergic nervous system in learning and memory: Prospects for development of an effective treatment strategy for senile dementia. Neurobiol Aging 9:627–638
Altman HJ, Nordy DA, Ogren SO (1984): Role of serotonin in memory: Facilitation by alaproclate and zimeldine. Psychopharmacology 84:496–502
Altman HJ, Stone WS, Ogren SO (1987): Evidence for a possible functional interaction between serotonergic and cholinergic mechanisms in memory retreival. Behav Neural Biol 48:49–62
Andrade R, Aghajanian GK (1985): Opiate- and alpha2-adrenoceptor-induced hyperpolarization of locus ceruleus neurons in brain slices: Reversal by cyclic adenosine 3′:5′-monophosphate analogues. J Neurosci 5:2359–2364
Aou S, Oomura Y, Nishino H (1983a): Influence of acetylcholine on neuronal activity in monkey orbital cortex during bar press feeding task. Brain Res 275:178–182
Aou S, Oomura Y, Nishino H, Inokuchi A, Mizuno Y (1983b): Influence of catecholamines on reward-related neuronal activity in monkey orbitofrontal cortex. Brain Res 267:165–170
Arai H, Kosaka K, Iizuka R (1984): Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer’s-type dementia. J Neurochem 43:388–393
Arnsten AFT, Goldman-Rakic PS (1985a): Catecholamines and cognitive decline in aged nonhuman primates. Ann NY Acad Sci 444:218–234
Arnsten AFT, Goldman-Rakic PS (1985b): α2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 230:1273–1279
Arnsten AFT, Cai JX, Goldman-Rakic PS (1988): The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: Evidence for alpha-2 receptor subtypes. J Neurosci 8:4287–4298
Baker GB, Reynolds GP (1989): Biogenic amines and their metabolites in Alzheimer’s disease: Noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid depleted in hippocampus but not in substantia innominata. Neurosci Lett 100:335–339
Bakhit C, Benoit R, Bloom FE (1983): Effects of cysteamine on pro-somatostatin related peptides. Regul Pept 6:169–177
Beal MF, Svendsen CN, Bird ED, Martin JB (1987): Somatostatin and neuropeptide Y are unaltered in the amygdla in schizophrenia. Neurochem Pathol 6:169–176
Beani L, Tanganelli T, Bianchi C (1986): Noradrenergic modulation of cortical acetylcholine release in both direct and gamma-aminobutyric acid-mediated. J PET 236:230–236
Beller SA, Overall JE, Swann AC (1985): Efficacy of oral physostigmine in primary degenerative dementia. Psychopharmacology 87:147–151
Bergman I, Brane G, Gottfries CG, Josteil KG, Karlsson I, Svennerholm L (1983): Alaproclate: A pharmacokinetic and biochemical study in patients with dementia of the Alzheimer type. Psychopharmacology 80:279–283
Bhat RV, Turner SL, Marks MJ, Collins AC (1990): Selective changes in sensitivity to cholinergic agonists and receptor changes elicited by continuous physostigmine infusion. J Pharmacol Exp Ther 255:187–196
Bigl V, Arendt T, Fischer S, Werner M, Arendt A (1987): The cholinergic system in aging. Gerontology 33:172–180
Bondareff W, Mountjoy CQ, Roth M (1982): Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus in senile dementia). Neurology 32:164–168.
Botwinick CY, Quartermain D (1974): Recovery from amnesia induced by pre-test injection of monoamine oxidase inhibitors. Pharm Biochem Behav 2:375–379
Bowen DM, Allen SJ, Benton JS, Goodhardt MJ, Haan EA, Palmer AM, Sims NR, Smith CC, Spillane JE, Esiri MM, Neary D, Snowden JS, Wilcock GK, Davison AN (1983): Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer’s disease. J Neurochem 41:266–272
Brown MR, Fisher LA, Sawchenko PE, Swanson LW, Vale W (1983): Biological effects of cysteamine: Relationship to somatostatin depletion. Regul Pept 5:163–174
Cross AJ (1990): Serotonin in Alzheimer-type dementia and other dementing illnesses. Ann NY Acad Sci 600:405–451
Cross AJ, Deakin JFW (1985): Cortical serotonin receptor subtypes after lesions of ascending cholinergic neurons in rat. Neurosci Lett 60:261–265
Cross AJ, Crow TJ, Johnson JA, Joseph MH, Perry EK, Perry RH, Blessed G, Tomlinson BE (1983): Monoamine metabolism in senile dementia of Alzheimer’s type. J Neurol Sci 60:383–392
Cross AJ, Crow TJ, Ferrier IN, Johnson JA, Bloom SR, Crosellis JA (1984): Serotonin receptor changes in dementia of the Alzheimer type. J Neurochem 43:1574–1581
Cross AJ, Crow TJ, Ferrier IN, Johnson JA (1986): The selectivity of the reduction of serotonin S2 receptors in Alzheimer-type dementia. Neurohiol Aging 7:3–7
Cutler NR, Haxby J, Kay AD, Narang PK, Lesko LJ, Costa JL, Ninos M, Linnoila M, Potter WZ, Renfrew JW, et al. (1985): Evaluation of zimeldine in Alzheimer’s disease. Cognitive and biochemical measures. Arch Neurol 42:744–748
Davies P, Terry RD (1981): Cortical somatostatin-like immunoreactivity in cases of Alzheimer’s disease and senile dementia of Alzheimer’s type. Neurobiol Aging 2:9–14
Davies P, Katzman R, Terry RD (1980): Reduced somatostatin-like-immunoreactivity in cerebral cortex from cases of Alzheimer’s disease Alzheimer’s senile dementia. Nature (London) 288:279–280
Decker MW, Gallager M (1987): Scopolamine-disruption of radial arm maze performance: Modification by noradrenergic depletion. Brain Res 417:59–69
Decker MW, McGaugh JL (1991): The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 7:151–168
Dekker AJAM, Connor DJ, Thal LJ (1991): The role of cholinergic projections from the nucleus basalis in memory. Neurosci Biobehav Rev 15:299–317
Dewar D, Graham DI, McCulloch J (1990): 5 HT2 receptors in dementia of Alzheimer type: A quantitative autoradiographic study of frontal cortex and hippocampus. J Neural Transm Park Dis Dement Sect 2:129–137
Doucette R, Fisman M, Hachinski VC, Mersky H (1986): Cell loss from the nucleus basalis of Meynert in Alzheimer’s disease. Can J Neurol Sci 13:435–440
Egan TM, North RA (1985): Acetylcholine acts on m2-muscarinic receptors to excite rat locus coeruleus neurons. Br J Pharmac 85:733–735
Egan TM, Henderson G, North RA, Williams JT (1983): Noradrenaline-mediated synaptic inhibition in rat locus coeruleus neurons. J Physiol 345:477–488
Engberg G, Svensson TH (1980): Pharmacological analysis of a cholinergic receptor mediated regulation of brain norepinephrine neurons. J Neural Trans 49:137–150
Fine A, Dunnett SB, Bjorklund A, Iversen SD (1985): Cholinergic ventral forebrain grafts into the neocortex improve passive avoidance memory in a rat model of Alzheimer disease. Proc Natl Acad Sci USA 82:5227–5230
Flood JF, Cherkin A (1987): Fluoxetine enhances memory processing in mice. Psychopharmacology 93:36–43
Fornal CA, Jacobs BL (1988): Physiological and behavioral correlates of serotonergic single-unit activity. In: Neuronal Serotonin, Osborn NN, Hamon M, eds. New York: John Wiley, pp 305–345
Forno LS, Eng LF, Selkoe DJ (1989): Pick bodies in the locus ceruleus. Acta Neuropathol. (Berlin) 79:10–17
German DC, White CL, Sparkman DR (1987): Alzheimer’s disease: Neurofibrillary tangles in nuclei that project to the cerebral cortex. Neuroscience 21:305–312
Giacobini E (1990): The cholinergic system in Alzheimer disease. Prog Brain Res 84:321–332
Goedert M, Fine A, Hunt SP, Ullrich A (1986): Nerve growth factor mRNA in peripheral and central rat tissue and in the human central nervous system. Lesion effects in the rat brain and levels in Alzheimer’s disease. Soc Neurosci Abst 12.1:299
Gold, PE, Zornetzer SF (1983): The mnemon and its juices: Neuromodulation of memory processes. Behav Neural Biol 38:151–189
Gottfries CG (1990a): Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer’s dementia. J Neural Trans [Suppl] 30:33–43
Gottfries CG (1990b): Brain monoamines and their metabolites in dementia. Acta Neurol Scand Suppl 129:8–11
Gottfries CG, Adolfsson R, Aquilonius SM, Carlsson A, Eckernas SA, Nordberg A, Oreland L, Svennerholm L, Wiberg A, Winblad B (1989): Biochemical changes in dementia disorders of the Alzheimer type (AD/SDAT). Neurobiol Aging 4:261–271
Haroutunian V, Barnes E, Davis KL (1985a): Cholinergic modulation of memory in rats. Psychopharmacology 87:266–271
Haroutunian V, Kanof P, Davis KL (1985b): Pharmacological alleviation of cholinergic lesions induced memory deficits in rats. Life Sci 37:945–952
Haroutunian V, Kanof PD, Davis KL (1989a): Attenuation of nucleus basalis of Meynert lesion-induced cholinergic deficits by nerve growth factor. Brain Res 487:200–203
Haroutunian V, Kanof PD, Davis KL (1989b): Interactions of forebrain cholinergic and somatostatinergic systems in the rat. Brain Res 496:98–104
Haroutunian V, Kanof PD, Tsuboyama GK, Campbell GA, Davis KL (1986): Animal models of Alzheimer’s disease: Behavior, pharmacology, transplants. Can J Neurol Sci 13:385–393
Haroutunian V, Mantin R, Campbell GA, Tsuboyama GK, Davis KL (1987): Cysteamineinduced depletion of central somatostatin-like immunoactivity: Effects on behavior, learning, memory and brain neurochemistry. Brain Res 403:234–242
Haroutunian V, Kanof PD, Tsuboyama G, Davis KL (1990a): Restoration of cholinomimetic activity by Clonidine in cholinergic plus noradrenergic lesioned rats. Brain Res 507:261–266
Haroutunian V, Mantin R, Kanof PD (1990b): Frontal cortex as the site of action of physostigmine in nbM-lesioned rats. Physiol Behav 47:203–206
Haroutunian V, Santucci AC, Davis KL (1990c): Implications of multiple transmitter system lesions for cholinomimetic therapy in Alzheimer’s disese. Prog Brain Res 84:333–346
Haroutunian V, Wallace WC, Davis KL (1991): Nucleus basalis lesions and recovery. In: Cholinergic Basis for Alzheimer Therapy, Giacobini E, Becker R, eds. Boston: Birkhäuser, pp 120–125
Huygens P, Baratti CM, Gardella JL, Filinger E (1980): Brain catecholamine modifications. The effects on memory facilitation induced by oxotremorine in mice. Psychopharmacology 69:291–294
Ichimiya Y, Arai H, Kosaka K, Iizuka R (1986): Morphological and biochemical changes in the cholinergic and monoaminergic systems in Alzheimer-type dementia. Acta Neuropathol (Bed) 70:112–116
Jansen KL, Faull RL, Dragunow M, Synek BL (1990): Alzheimer’s disease: changes in hippocampal N-methyl-D-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors—an autoradiographic study. Neuroscience 39:613–627
Kohler C (1984): The distribution of serotonin binding sites in the hippocampal region of the rat brain. An autoradiographic study. Neuroscience 13:667–680
Koshimura K, Kato T, Yohyama I, Nakamura S, Kameyama M (1987): Correlation of choline acetyltransferase activity between the nucleus basalis of Meynert and the cerebral cortex. Neurosci Res 4:330–336
Lakoski JM, Aghajanian GK (1985): Effects of ketanserin on neuronal responses to serotonin in the prefrontal cortex, lateral geniculate and dorsal raphe nucleus. Neuropharmacology 24:265–273
Lewander T, Joh TH, Reis DJ (1977): Tyrosine hydroxylase: Delayed activation in central noradrenergic neurons and induction in adrenal medulla elicited by stimulation of central cholinergic receptors. J PET 200:523–534
Madison DV, Nicoll RA (1984): Control of the repetitive discharge of CA1 pyramidal neurons in vitro. J Physiol 354:319–331
Mair RG, McEntee WJ (1986): Cognitive enhancement in Korsakoff’s psychosis by Clonidine: A comparison with I-dopa and ephedrine. Psychopharmacology 88:374–380
Mandel RJ, Chen AD, Connor DJ, Thal LJ (1989): Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: Effects on performance in the water maze task and cortical cholinergic markers. J Pharmacol Exp Ther 251:612–619
Mann DM, Lincoln J, Yates PO, Stamp JE, Toper S, Maruyama Y, Oshima T, Nakajima EI (1980): Changes in the monoamine containing neurons of the human CNS in senile dementia. Simultaneous determination of catecholamines in rat brain by reversedphase liquid chromatography with electrochemical detection. Br J Psychiat Life Sci 26:1115–1120
Mann DMA, Lincoln J, Yates PO, Stamp JE, Toper S (1983): Changes in the monoamine containing neurones of the human CNS in senile dementia. J Neurol Neurosurg Psychiat 46:96–102
Mann DM, Yates PO, Marcyniuk B (1985): Correlation between senile plaque and neurofibrillary tangle counts in cerebral cortex and neuronal counts in cortex and subcortical structures in Alzheimer’s disease. Neurosci Lett 56:51–55
Mann DM, Yates PO, Marcyniuk B (1986a): A comparison of nerve cell loss in cortical and subcortical structures in Alzheimer’s disease. J Neurol Neurosurg Psychiat 49:310–312
Marcyniuk B, Mann DM, Yates PO (1989): The topography of nerve cell loss from the locus caeruleus in elderly persons. Neurobiol Aging 10:5–9
Mason ST (1979): Noradrenaline: Reward or extinction? Neurosci Biobehav Rev 3:1–10
Mason ST, Fibiger HC (1979): Possible behavioral function for noradrenaline-acetylcholine interaction in brain. Nature (London) 277:396–397
McEntee WJ, Mair RG (1980): Memory enhancement in Korsakoff’s psychosis by Clonidine: Further evidence for a noradrenergic deficit. Ann Neurol 7:466–470
McGeer PL, McGeer EG, Suzuki J, Dolman CE, Nagai T (1984): Aging, Alzheimer’s disease, and the cholinergic system of the basal forebrain. Neurology 34:741–745
NcNaughton N, Mason ST (1980): The neuropsychology and neuropharmacology of the dorsal ascending noradrenergic bundle—A review. Prog Neurobiol 14:157–219
Mitchell IJ, Stuart AM, Slater P, Unwin HP, Crossman AR (1984): Autoradiographic demonstration of 5HT1 binding sites in the primate basal nucleus of Meynert. Eur J Pharmacol 104:189–190
Murray CL, Fibiger HC (1985): Learning and memory deficits after lesions of the nucleus basalis magnocellularis: Reversal by physostigmine. Neuroscience 19:1025–1032
Normile HJ, Jenden DJ, Kuhn DM, Wolf WA, Altman HJ (1990): Effects of combined serotonin depletion and lesions of the nucleus basalis magnocellularis on acquisition of a complex spatial discrimination task in the rat. Brain Res 536:245–250
Ogren SO (1985a): Evidence for a role of brain serotonergic neurotransmission in avoidance learning. Acta Physiol Scand Suppl 544:1–71
Ogren SO (1986a): Analysis of the avoidance learning deficit induced by serotonin releasing compound p-chloroamphetamine. Brain Res Bull 16:645–660
Ogren SO (1986b): Serotonin receptor involvement in the avoidance learning deficit caused by p-chloroamphetamine-induced serotonin release. Acta Physiol Scand 126:449–462
Ogren SO, Johansson C, Magnusson O (1985a): Forebrain serotonergic involvement in avoidance learning. Neurosci Lett 58:305–309
Ogren SO, Nordstrom O, Danielsson E, Peterso LL, Bartfai T (1985b): In vivo and in vitro studies on the potentiation of muscarinic receptor stimulation by alaprocite, a selective 5-HT uptake blocker. J Neural Trans 61:1–20
Palacios JM, Probst A, Cortes R (1983): The distribution of serotonin receptors in the human brain: High density of [3H]LSD binding sites in the raphe nuclei of the brainstem. Brain Res 274:150–155
Palmer AM, Francis PT, Bowen DM, Neary JS, Mann DMA, Snowden JS (1987a): Catecholaminergic neurons assessed ante-mortem in Alzheimer’s disease. Brain Res 414:365–375
Palmer AM, Wilcock GK, Esiri MM, Francis PT, Bowen DM (1987b): Monoaminergic innervation of the frontal and temporal lobes in Alzheimer’s disease. Brain Res 401:231–238
Palmer AM, Stratmann GC, Procter AW, Bowen DM (1988): Possible neurotransmitter basis of behavioral changes in Alzheimer’s disease. Ann Neurol 23:616–620
Pazos A, Palacios JM (1985): Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 346:205–230
Pazos A, Cortes R, Palacios JM (1985): Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res. 346:231–249
Perry EK (1987): Cortical neurotransmitter chemistry in Alzheimer’s disease. In: Psychopharmacology: The Third Generation of Progress, Meltzer HY, ed. New York: Raven Press, pp 887–896
Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1978): Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2:1457–1459
Perry EK, Tomlinson BE, Blessed G, Perry RH, Cross AJ, Crow TJ (1981): Neuropathological and biochemical observations on the noradrenergic system in Alzheimer’s disease. J Neurol Sci 51:279–337
Perry EK, Perry RH, Candy JM, Fairbairn AF, Blessed G, Dick DJ, Tomlinson BE (1984): Cortical serotonin-S2 receptor binding abnormalities in patients with Alzheimer’s disease: Comparisons with Parkinson’s disease. Neurosci Lett 51:353–357
Pomponi M, Giacobini E, Brufani M (1990): Present state and future development of the therapy of Alzheimer disease. Aging (Milano) 2:125–153
Quartermain D, Botwinick CY (1975): Role of biogenic amines in the reversal of cycloheximide-induced amnesia. J Comp Physiol Psychol 88:386–401
Quartermain D, Freedmen LS, Botwinick CY, Gutwein BM (1977): Reversal of cycloheximide-induced amnesia by adrenergic receptor stimulation. Physiol Biochem Behav 7:259–267
Quartermain D, Judge ME, Leo P (1988): Attenuation of forgetting by pharmacological stimulation of aminergic neurotransmitter systems. Pharm Biochem Behav 30:77–81
Quirion R, Richard J, Dam TV (1985): Evidence for the existance of serotonin type 2 receptors on cholinergic terminals in rat cortex. Brain Res 33:345–349
Ragawski MA, Aghajanian GK (1980): Norepinephrine and serotonin: Opposit effects on the activity of lateral geniculate neurons evoked by optic pathway stimulation. Exp Neurol 69:678–694
Reinikainen KJ, Paljarvi L, Huuskonen M, Soininen H, Laakso M, Riekkinen PJ (1988): A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer’s disease. J Neurol Sci 84:101–116
Reinikainen KJ, Soininen H, Riekkinen PJ (1990): Neurotransmitter changes in Alzheimer’s disease: Implications to diagnostics and therapy. J Neurosci Res 27:576–586
Robinson S (1986): 6-hydroxydopamine lesions of the ventral noradrenergic bundle blocks the effects of amphetamine on hippocampal acetylcholine. Brain Res 397:181–184
Robinson SE, Cheney DL, Costa E (1978): Effects of normifensine and other antidepressant drugs on acetylcholine turnover in various regions of rat brain. Naunyn Schmiedebergs Arch Pharmacol 304:263–269
Robinson SE, Rice MA, Hambrecht KL (1986): Effect of intrastriatal injection of diisopropylfluorophosphate on acetylcholine, dopamine and serotonin metabolism. J Neurochem 46:1632–1638
Rossor MN, Emson PC, Montjoy CQ, Roth M, Iversen LL (1980): Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer’s type. Neurosci Lett 20:373–377
Sagar SM, Landry D, Millard WJ, Badger TM, Arnold MA, Martin JB (1982): Depletion of somatostatin-like immunoreactivity in the rat central nervous system by cysteamine. J Neurosci 2:225–231
Santucci AC, Kanof PD, Haroutunian V (1990): Serotonergic modulation of cholinergic systems involved in learning and memory in rats. Dementia 1:151–155
Saper CB, German DC, White CL (1985): Neuronal pathology in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer’s type: Possible role in cell loss. Neurology 35:1089–1095
Shimohama S, Taniguchi T, Fujiwara M, Kameyama M (1986): Biochemical characterization of a-adrenergic receptors in human brain and changes in Alzheimer-type dementia. J Neurochem 47:1294–1301
Sparks DL (1989): Aging and Alzheimer’s disease. Altered cortical serotonergic binding. Arch Neurol 46:138–140
Sparks DL, DeKosky ST, Markesbery WR (1988): Alzheimer’s disease. Aminergiccholinergic alterations in hypothalamus. Arch Neurol 45:994–999
Summers WK, Viesselman JO, Marsh GM, Candelora K (1981): Treatment of Alzheimerlike dementia: Pilot study in twelve patients. Biol. Psychiatr 16:145–153
Vecsei L, Kiraly C, Bollok I, Nagy A, Verga J, Penke B, Telegdy G (1984): Comparative studies with somatostatin and cysteamine in different behavioral tests with rats. Pharmacol Biochem Behav 21:833–837
Vizi ES (1980): Modulation of cortical release of acetylcholine by noradrenaline released from nerve terminals arising from the rat locus coeruleus. Neuroscience 5:2139–2144
Waterhouse BD, Moises HC, Woodward D (1980): Noradrenergic modulation of somatosensory cortical neuronal responses to iontophoretically applied putative neurotransmitters. Exper Neurol 69:30–49
Waterhouse BD, Moises HC, Woodward D (1981): Alpha-receptor-mediated facilitation of somatosensory cortical neuronal responses to excitatory synaptic inputs and iontophoretically applied acetylcholine. Neuropharmacology 20:907–920
Waterhouse BD, Moises HC, Woodward DJ (1986): Interaction of serotonin with somatosensory cortical neuronal responses to afferent synaptic inputs and putative neurotransmitters. Brain Res Bull 17:507–518
Wenk GL, English KL (1986): [3H]Ketanserin (serotonin type 2) binding increases in rat cortex following basal forebrain lesions with ibotenic acid. J Neurochem 47:845–850
Wenk GL, Olton DS (1987): Basal forebrain cholinergic neurons and Alzheimer’s disease. In: Animal Models of Dementia: A Synaptic Neurochemical Perspective, Coyle JT, ed. New York: Alan R. Liss, pp 81–102
Wenk G, Hughey D, Boundy V, Kim A, Walker L, Olton D (1987): Neurotransmitters and memory: Role of cholinergic, serotonergic, and noradrenergic systems. Behav Neurosci 3:325–332
Westfall T (1974): Effect of muscarinic agonists on the release of 3H-norepinephrine and 3H-dopamine by potassium and electrical stimulation from rat brain slices. Life Sci 14:1641–1652
Whitehouse PJ (1986): Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson’s disease and Alzheimer’s disease. Adv Neurol 45:393–397
Wilcock GK, Esiri MM, Bowen DM, Hughes AO (1988): The differential involvement of subcortical nuclei in senile dementia of Alzheimer’s type. J Neurol Neurosurg Psychiatry 51:842–849
Yamamoto T, Hirano A (1985): Nucleus raphe dorsalis in Alzheimer’s disease: Neurofibrillary tangles and loss of large neurons. Ann Neurol 17:573–577
Yates CM, Simpson J, Gordon A, Maloney AFJ, Allison Y, Ritchie IM, Urquhart A (1983): Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimertype dementia and Down’s syndrome. Brain Res 280:119–126
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Birkhäuser Boston
About this chapter
Cite this chapter
Haroutunian, V., Santucci, A.C., Davis, K.L. (1992). Neurotransmitter Interactions and Responsivity to Cholinomimetic Agents. In: Levin, E.D., Decker, M.W., Butcher, L.L. (eds) Neurotransmitter Interactions and Cognitive Function. Birkhäuser Boston. https://doi.org/10.1007/978-1-4615-9843-5_8
Download citation
DOI: https://doi.org/10.1007/978-1-4615-9843-5_8
Publisher Name: Birkhäuser Boston
Print ISBN: 978-1-4615-9845-9
Online ISBN: 978-1-4615-9843-5
eBook Packages: Springer Book Archive